Anika Therapeutics reaffirms FY25 adjusted EBITDA view of down 3% to up 3%

Anika maintains 2025 revenue ranges by channel as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up 12% to 18% year-over-year; OEM Channel, unchanged, of $62 to $65 million, down 16% to 20% year-over-year; Anika maintains Adjusted EBITDA of -3% to 3%